Clindesse (Clindamycin Phosphate) Patent Expiration, LOE Window & CMS Spending

Clindesse (Clindamycin Phosphate) by Padagis Us: FDA Orange Book LOE 2026-12-02, 1 AB generics, $955K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorPadagis Us
FDA Application & PathwayN050793 (NDA)
Exclusivity / Cliff HorizonImmediate Cliff (2025-2027)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2026-12-02
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors1
2024 CMS Total Public Spend$955K
2024 Medicare Part D Spend$56K
2024 Medicaid Spend$898K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel